These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 7831531)
1. The classification of ductal carcinoma in situ and its association with biological markers. Bobrow LG; Happerfield LC; Gregory WM; Springall RD; Millis RR Semin Diagn Pathol; 1994 Aug; 11(3):199-207. PubMed ID: 7831531 [TBL] [Abstract][Full Text] [Related]
2. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Zafrani B; Leroyer A; Fourquet A; Laurent M; Trophilme D; Validire P; Sastre-Garau X Semin Diagn Pathol; 1994 Aug; 11(3):208-14. PubMed ID: 7831532 [TBL] [Abstract][Full Text] [Related]
3. Ductal carcinoma in situ: assessment of necrosis and nuclear morphology and their association with biological markers. Bobrow LG; Happerfield LC; Gregory WM; Millis RR J Pathol; 1995 Aug; 176(4):333-41. PubMed ID: 7562248 [TBL] [Abstract][Full Text] [Related]
4. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366 [TBL] [Abstract][Full Text] [Related]
5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study. Ottesen GL APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968 [TBL] [Abstract][Full Text] [Related]
6. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness. Wärnberg F; Nordgren H; Bergkvist L; Holmberg L Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839 [TBL] [Abstract][Full Text] [Related]
7. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers. Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058 [TBL] [Abstract][Full Text] [Related]
8. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998 [TBL] [Abstract][Full Text] [Related]
9. The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast: a study of a large cohort of patients treated with surgery alone. Cornfield DB; Palazzo JP; Schwartz GF; Goonewardene SA; Kovatich AJ; Chervoneva I; Hyslop T; Schwarting R Cancer; 2004 Jun; 100(11):2317-27. PubMed ID: 15160334 [TBL] [Abstract][Full Text] [Related]
10. Correlation of p53 and cerbB2 expression and hormonal receptor status with clinicopathologic parameters in ductal carcinoma in situ of the breast. Tan PH; Chuah KL; Chiang G; Wong CY; Dong F; Bay BH Oncol Rep; 2002; 9(5):1081-6. PubMed ID: 12168077 [TBL] [Abstract][Full Text] [Related]
11. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ. Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051 [TBL] [Abstract][Full Text] [Related]
12. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma. Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793 [TBL] [Abstract][Full Text] [Related]
13. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study]. Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497 [TBL] [Abstract][Full Text] [Related]
15. Estrogen and progesterone receptor and c-erbB-2 oncoprotein analysis in pure in situ breast carcinoma: an immunohistochemical study. Wilbur DC; Barrows GH Mod Pathol; 1993 Mar; 6(2):114-20. PubMed ID: 8097877 [TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161 [TBL] [Abstract][Full Text] [Related]
17. Expression of p53 protein in infiltrating and in-situ breast carcinomas. Walker RA; Dearing SJ; Lane DP; Varley JM J Pathol; 1991 Nov; 165(3):203-11. PubMed ID: 1684809 [TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha expression in ductal carcinoma in situ of the breast: a preliminary study. Shpitz B; Bomstein Y; Zehavi T; Bernheim J; Liverant S; Kaufman Z; Buklan G; Klein E Hum Pathol; 2000 Oct; 31(10):1249-54. PubMed ID: 11070118 [TBL] [Abstract][Full Text] [Related]
19. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone. Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090 [TBL] [Abstract][Full Text] [Related]
20. Breast carcinoma in women 35 years and younger: a pathological study. Fernandopulle SM; Cher-Siangang P; Tan PH Pathology; 2006 Jun; 38(3):219-22. PubMed ID: 16753742 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]